TCT 2023 Insights: Primary Outcomes of the Esprit BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions - The LIFE-BTK Trial | VuMedi

TCT 2023 Insights

TCT 2023 Insights: Primary Outcomes of the Esprit BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions - The LIFE-BTK Trial

By TCT 2023 Insights FEATURING Ramon Varcoe

By TCT 2023 Insights FEATURING Ramon Varcoe

0 views

October 26, 2023

Comments 0

Login to view comments. Click here to Login